Holen Sie sich die Stockscreener-App
25.86
2.99%
0.75
Schlusskurs vom Vortag:
$25.11
Offen:
$25.63
24-Stunden-Volumen:
1.04M
Relative Volume:
1.88
Marktkapitalisierung:
$1.78B
Einnahmen:
$71.30M
Nettoeinkommen (Verlust:
$-354.80M
KGV:
-4.6261
EPS:
-5.59
Netto-Cashflow:
$-356.00M
1W Leistung:
+15.04%
1M Leistung:
-2.67%
6M Leistung:
-28.07%
1J Leistung:
+20.78%
1-Tages-Spanne:
$25.13
$26.55
1-Wochen-Bereich:
$21.17
$26.55
52-Wochen-Spanne:
$21.17
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ARVN | 25.86 | 1.78B | 71.30M | -354.80M | -356.00M | -5.59 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Metastatic Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Merck, Arvinas Androgen Receptor, Novartis, UNICANCER, Aragon Pharma, Mark Stein - Barchart
Pfizer, Arvinas delay late-stage trial for breast cancer therapy - MSN
Metastatic Prostate Cancer Market to Show Remarkable Growth - openPR
Leerink Partnrs Issues Negative Outlook for Arvinas Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out - AccessWire
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire
Unveiling 4 Analyst Insights On Arvinas - Benzinga
Arvinas shares target cut to $62 on delayed trial data By Investing.com - Investing.com Canada
Arvinas shares target cut to $62 on delayed trial data - Investing.com
Arvinas reports delay in breast cancer trial results - Investing.com India
Arvinas reports delay in breast cancer trial results By Investing.com - Investing.com UK
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Stephens Begins Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat
Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN
RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com
Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat
Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arvinas Inc-Aktie (ARVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Houston John G | President and CEO |
Feb 23 '24 |
Sale |
47.05 |
5,196 |
244,472 |
1,036,681 |
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
| Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):